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Abstract. Bone morphogenetic protein-6 (BMP-6) be- 
longs to the family of TGF-[3-related growth factors. In 
the developing epidermis, expression of BMP-6 coin- 
cides with the onset of stratification. Expression per- 
sists perinatally but declines after day 6 postpartum, al- 
though it can still be detected in adult skin by reverse 
transcriptase-polymerase chain reaction (RT-PCR) 
analysis. We constitutively overexpressed BMP-6 in su- 
prabasal layers of interfollicular epidermis in transgenic 
mice using a keratin 10 promoter. All mice expressing 
the transgene developed abnormalities in the skin, indi- 
cating an active transgene-derived factor. Depending 
on the pattern of transgene expression, the effects on 
proliferation and differentiation were completely oppo- 
site. Strong and uniform expression of the BMP-6 
transgene resulted in severe repression of cell prolifera- 
tion in embryonic and perinatal epidermis but had mar- 
ginal effects on differentiation. Weaker and patchy ex- 
pression of the transgene evoked strong hyperproliferation 
and parakeratosis in adult epidermis and severe pertur- 
bations of the usual pattern of differentiation. These 
perturbations included changes in the expression of 
keratins and integrins. Together with an inflammatory 
infiltrate both in the dermis and in the epidermis, these 
aspects present all typical histological and biochemical 
hallmarks of a human skin disease: psoriasis. 
B 
ONE morphogenic protein-6 (BMP-6) 1 is a member 
of the TGF-[3  superfamily of growth factors (Ly- 
ons et al., 1989a; Lyons et al., 1991). These signal- 
ling molecules are  produced as precursors  that are  pro- 
teolytically cleaved to yield the  carboxy-terminal active 
peptide. The mature factor binds to specific cell surface re- 
ceptors on the target cells and exerts multiple biological 
activities in vitro and in vivo (Sato et al., 1990; Massague et 
al., 1991; Drozdoff et al., 1994; Gitelman et al., 1994, 1995; 
Perides et  al.,  1994; Hughes et al.,  1995).  Expression  of 
BMP-6  in  mammals  was  demonstrated  in  various  cell 
types of the nervous system, smooth muscle cells, growth 
plate chondrocytes, neonatal bronchiolar epithelium, cor- 
nea, and epidermis (Lyons et al.,  1989b; Wall et al., 1993; 
Schluesener and Meyermann, 1994; Carey and Liu, 1995; 
Schluesener  and  Meyermann,  1995; Schluesener  et  al., 
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1995; Tomizawa et al., 1995). In murine epidermis, expres- 
sion of BMP-6 is first seen after day 15 postcoitum and ac- 
companies the acquisition of a  multilayered structure of 
this  organ.  BMP-6  synthesis is  confined to  postmitotic 
keratinocytes undergoing terminal differentiation in  the 
suprabasal compartment of interfollicular epidermis. Ex- 
pression persists perinatally and declines to low levels in 
adult skin after day 6  postpartum  (Lyons et  al.,  1989b; 
Wall et al., 1993). 
Proliferation and differentiation in the epidermis is tightly 
controlled in order to maintain homeostasis. Cell division 
is usually restricted to the basal layer, whereas cells in the 
suprabasal layers are quiescent and in the process of ter- 
minal differentiation. This process can be followed by a 
switch in expression of marker keratins from the basal cell 
specific keratins 5 and  14 to the suprabasal cell specific 
keratins 1 and 10. (Fuchs and Green, 1980; Tseng et al., 
1982;  Woodcock-Mitchell et  al.,  1982; Nelson  and  Sun, 
1983; Skerrow and Skerrow,  1983).  Perturbations in the 
distribution of proliferating and differentiating cells and 
the usual pattern  of terminal differentiation are seen in 
many pathological skin conditions of humans, most nota- 
bly in psoriasis. Psoriatic skin is characterized by epider- 
mal thickening and the presence of nucleated cells in the 
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tential of suprabasal cells (Weinstein and VanScott, 1965; 
Lavker and Sun, 1983; Leigh et al.,  1985). In addition to 
parahyperkeratosis, a change in the expression of marker 
keratins is observed: suprabasal localization of the basal 
type keratin 14 including the outermost layers of the stra- 
tum corneum, partial repression of the differentiation as- 
sociated keratins 1 and 10, and interfollicular induction of 
the hyperproliferative marker keratins 6 and 16 (Weiss et 
al., 1984; Stoler et al., 1988). Similarly, the expression do- 
mains of some integrin subunits are expanded from basal 
into suprabasal layers in psoriatic lesions (for review see 
Watt  and  Hertle,  1994).  Integrins  could be  directly in- 
volved in  lesion formation because  ectopic integrin  ex- 
pression as well as a hypomorphic mutation in the leuko- 
cyte integrin subunit 132/CD18 induce plaques in mice very 
similar to  human psoriatic  lesions  (Lever  and  Schaum- 
burg-Lever, 1975; Wade and Finan, 1990; Carroll et  al., 
1995; Bullard et al., 1996). 
Alterations in the expression patterns for several growth 
factors, growth factor receptors, and cytokines have been 
observed  in  psoriatic skin including TGF-a  and TGF-13 
(Elder et al., 1989; Kane et al., 1990). However, transgenic 
mice with epidermal changes in growth factor expression 
including TGF-et and TGF-~3 so far failed to develop psori- 
atic lesions (Vassar et al., 1991; Dominey et al., 1993; Sell- 
heyer et al.,  1993; Cui et al.,  1995).  The TGF-13-related 
factor BMP-6 appears in differentiating keratinocytes be- 
fore the expression of the differentiation markers, keratins 
1 and 10, and has so far been demonstrated to inhibit kera- 
tinocyte proliferation only in vitro (Drozdoff et al., 1994). 
Possible  functions in  triggering  terminal differentiation, 
however, or possible  roles in disturbances  of epidermal 
homeostasis remained uncertain. 
To analyze functions of BMP-6 in controlling prolifera- 
tion and differentiation of epidermal cells in vivo and to 
evaluate the possible role of this TGF-f3-related molecule 
in  the  etiology of psoriatic  skin  diseases,  we  generated 
transgenic mice overexpressing BMP-6 in suprabasal lay- 
ers of interfollicular epidermis using a keratin 10 promoter 
driven transgenic construct (Werner et al., 1993). The mi- 
totic response of the keratinocytes to BMP-6 in vivo was 
positive or negative depending on the pattern of transgene 
expression. In addition, animals of two independent lines 
developed lesions with all characteristics of human psoriasis. 
Materials and Methods 
Construction of the Expression Vector and Generation 
of Transgenic Mice 
The keratin 10-based expression vector and a human cDNA coding for 
BMP-6 had been described before (Wall et al., 1993; Werner et al., 1993; 
Drozdoff et al., 1994). The cDNA was inserted into the SmaI site between 
the beta-globin intron and the polyadenylation sequence from the human 
gene for growth hormone. The expression cassette was excised by KpnI 
digestion, gel purified, and used for pronuclear microinjection of fertilized 
eggs of strain FVB/N essentially as described (Hogan et al., 1986).  Off- 
springs were biopsied at the ears or tails. After DNA extraction, PCR- 
analysis was performed using primers derived  from the human BMP-6 
cDNA (5'-ctt ggt tca cct tat gaa ccc c-3') and from the poly(A) addition 
signal region from the human gene for growth hormone (5'-taa tcc cag caa 
ttt ggg agg c-3'). Subsequently, the samples were subjected to agarose gel 
electrophoresis to visualize the diagnostic fragment of size 480 bp. 
In Situ Hybridization and Reverse 
Transcriptase-Polymerase Chain Reaction Analysis 
In situ hybridization experiments were performed under high stringency 
conditions essentially as described (Jones et al., 1991)  with the following 
modification. Fresh tissue samples were fixed in methanol/dimethylsulfox- 
ide (4:1), dehydrated in ethanol and xylene, and embedded in paraffin for 
sectioning. After rehydration, the sections were  refixed with 4%  para- 
formaldehyde and hybridized to a 35S-labeled  cRNA probe complemen- 
tary to the sequence preceding the human growth hormone polyadenyla- 
tion signal (Werner et al., 1993). 
Reverse transcriptase-polymerase chain reaction  (RT-PCR)  analysis 
was performed using DNAse I-treated pools of total RNA from different 
tissues. Reverse transcription was accomplished using the RT-PCR kit 
(Stratagene, La Jolla, CA) according to the manufacturer's instructions. 
PCR was performed using vent (exo-) polymerase (New England Biolabs, 
Beverly, MA) with 64°C annealing temperature and 35 cycles. Primer B6 
(AGACCTGGGATGGCAGG) is derived from a part of the mature re- 
gion of BMP-6 that is identical in mouse and man (position 1473-1489 in 
the murine cDNA, Gitelman et al., 1994;  and position 1277-1293 in the 
human cDNA, Celeste et al., 1990).  The first reverse primer aB6 (AC- 
CATCCCGCqTCGCTGTGC) was derived from the 3'-untranslated se- 
quence of the murine BMP-6 cDNA (position 1855-1836; Gitelman et al., 
1994),  and  the  second  reverse  primer  pA  (GGAGTGGCAACTTC- 
CAGG) was derived from the region preceding the polyadenylation se- 
quence of the human gene for growth hormone (Werner et  al.,  1993). 
Thus, the primer  pair  B6/aB6  specifically amplifies murine BMP-6 se- 
quences yielding a  363-bp diagnostic band, and the primer pair  B6/pA 
specifically recognizes transgene-derived sequences yielding a 390-bp di- 
agnostic fragment.  In  both  cases,  the  amplified  sequences encompass 
nearly the entire parts of the mRNAs coding for the mature region of the 
growth factor. Primers for amplification of a 403-bp 13-actin cDNA frag- 
ment were  act1  (GTGGGCCGCTCTAGGCACCA) and act2 (TAGC- 
CCTCGTAGATGGGCACAG). 
Histology and Ultrastructural Analysis 
Hematoxilin, eosin, and chloroacetate esterase staining were performed 
according to  standard protocols.  For  transmission electron microscopy, 
tissues were fixed in 2.5% glutaraldehyde (pH 7.2) overnight, postfixed in 
1%  OsO4 for 2 h, and dehydrated in graded ethanol. After carrying the 
sections through propylene oxide as an intermedium, the tissues were em- 
bedded in agar 100 resin (PLANO, Wetzlar, Germany) and submitted to 
polymerization at 60°C for 24 h. Semithin and 80-nm ultrathin sections 
were cut with an ultramicrotome ultracut (Reichert Jung, Vienna, Aus- 
tria) and ultrathin sections were placed onto slit foils. Ultrastructural anal- 
ysis and photomicroscopy was performed with a  transmisssion electron 
microscope (model EM 410; Philips, Eindhoven, Netherlands). 
For  scanning electron  microscopy tissue, specimens were  fixed  and 
postfixed as described above. After dehydration in graded acetone and 
critical point drying (CPD 030; Balzers, S.P.A., Nordenstadt, Germany), 
specimens were  placed  onto  Leit  C-covered  metal  plates  (Neubauer, 
Miinster, Germany), sputtered with gold in a coating unit (model E5100; 
Polaron Instruments, Inc., Munich, Germany), and analyzed under a scan- 
ning electron microscope (model DSM962; Carl Zeiss Inc., Oberkochen, 
Germany). 
Immunostaining 
Fresh tissue samples were fixed in methanol/dimethylsulfoxide (4:1),  em- 
bedded in paraffin, and sectioned. Frozen sections for antiintegrin immu- 
nostaining were fixed in acetone. For double-label immunostaining with 
monoclonal antibodies specific for  keratin  14  and keratins  1/10  (clone 
CKB1 and clone 8.6 from Sigma Immunochemicals, Deisenhofen, Ger- 
many) the rehydrated paraffin sections were pretreated with pronase. An- 
tibody CKB1 (antikeratin 14) was used at a  1/200 dilution and antibody 
8.6 (antikeratins 1/10)  at a  1/400 dilution. Fluorochrome-labeled second- 
ary  antibodies (Nos.  115-165-071  and  115-015-075;  Dianova, Hamburg, 
Germany) were  used at  a  1/600  dilution. The rat monoclonal antibody 
specific for the ct  6 integrin subunit (GoH3 from Progen, Heidelberg, Ger- 
many; No. 10709) was used at a 1/2 dilution and the fluorochrome labeled 
secondary antibody (No. 212-166-082"  Dianova) was used at a 1/800 dilu- 
tion. The affinity purified polyclonal anti-BMP-6 antibody (Wall et al., 
1993) was used at a 1/200 dilution. A polyclonal antiserum raised against a 
carboxy-terminal peptide of mouse keratin 6 as described (Roop et al., 
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described previously (for references see Wall et al., 1993). 
For anti-proliferating cell-associated nuclear antigen (PCNA) staining, 
5 ~m paraffin sections were incubated with 1%  hydrogensuperoxide in 
methanol after dewaxing and refixed with 4% paraformaldehyde after re- 
hydration. The primary antibody (clone PC10, No. 32551A;  PharMingen, 
Hamburg, Germany; Garcia et al., 1989) was used at a 1/100 dilution and 
binding was visualized using the StreptAB-Complex/HRP-Duett System, 
according to the manufacturers  instructions (No.  K492;  DAKO, Ham- 
burg, Germany). 
BrdU Labeling Experiments 
These experiments were performed using the Cell Proliferation Kit (No. 
RPN20;  Amersham  Corp.,  Braunschweig,  Germany)  according to  the 
manufacturer's instructions with the following modifications: age matched 
transgenic animals and normal controls were sacrificed after 3 h of label- 
ing, and tissue samples were fixed with methanol/dimethylsulfoxide (4:1), 
embedded in paraffin, and sectioned. Rehydrated paraffin sections were 
then refixed with 4% paraformaldehyde and treated with pronase before 
incubation with the primary antibody-nuclease mix. 
Results 
Phenotypes of Transgenic Mice 
Transgenic founders carrying the BMP-6 expression vec- 
tor (Fig. 1) were identified by PCR analysis and fell into 
three classes: severely affected founders were born with a 
tightly stretched skin with a shiny and pergament like ap- 
pearance lacking dermatoglyphic patterning (Fig. 2 a). All 
three founder animals of this type were alive and feeding 
the  day  after  birth.  They  were  sacrificed  immediately. 
Four  moderately  affected  transgenic  founders  and  off- 
spring from two of those (lines VI-6-1 and VI-6-32) looked 
normal at birth but developed a shiny and flaky skin, start- 
ing six days after birth, which could be best observed in 
pigmented skin of transgenic FVB/N X  C57/B16 F1 pups 
(Fig. 2 b). 2-3 wk after birth, these mice developed lesions 
characterized  by  inflammatory processes.  These  lesions 
could first be observed on the  markedly thickened ears 
(Fig. 2, c and d) but also affected other body sites includ- 
ing dorsal and lateral skin. The condition worsened with 
age eventually encompassing the entire skin and was ac- 
companied by a progressive hair loss, flaky skin, and ab- 
_normalities of the nails (Fig. 2, c-e). Some animals of lines 
VI-6-1  and  VI-6-32  showed  a  growth  retardation  when 
compared  to  nontransgenic  littermates  (Fig.  2  b).  This 
variable growth  retardation  was  most  notably visible in 
large  litters.  Removal  of  nontransgenic  littermates  re- 
sulted in lean but approximately normally sized transgenic 
adults  (Fig.  2  c),  indicating  a  reduced  competitivity of 
these transgenic pups rather than a physiological problem 
in food uptake or processing. This assumption is strength- 
ened by the absence of histological abnormalities in oral 
mucosa or stomach epithelia in these transgenics (data not 
shown). In addition, full thickness grafts of transgenic dor- 
sal  skin  onto  nontransgenic  recipients  remained  hyper- 
keratotic, proving a  primary epidermal defect (data  not 
shown). Two additional transgenic founder mice (VI-6-19 
and VI-6-21) and their transgenic offspring showed no ab- 
normalities. 
Expression of BMP-6 in Skin and Other Epithelia 
Transgene expression was  analyzed by in situ hybridiza- 
tion experiments using a riboprobe derived from the re- 
gion preceding the polyadenylation signal  in the  human 
gene  for  growth  hormone.  Severely  affected  neonatal 
founders showed a  strong and uniform pattern of trans- 
gene expression in interfollicular epidermis (Fig. 3, a and 
a'). Higher power magnification demonstrated strong ac- 
cumulation of transgene-derived RNA in the suprabasal 
layers and exclusion from the basal layers (Fig. 3, b  and 
b'). By contrast, neonates of the moderately affected line 
VI-6-1  displayed a  much weaker  accumulation  of trans- 
gene derived RNA in the epidermis. In addition to gener- 
ally being weak, the pattern of expression was patchy but 
still properly confined to the suprabasal  layers (Fig. 3, c 
and c'). 
Endogenous  and  transgene-dependent  expression  of 
BMP-6 were compared in skin, oral mucosa, and stomach 
of adult mice by RT-PCR analysis. The specificity of the 
primer pair B6/aB6 for murine BMP-6 sequences and B6/ 
pA for transgene-derived sequences was verified using the 
transgene construct and a murine BMP-6 eDNA as tem- 
plates.  Starting  from equimolar  amounts  of templates, 
amplification with the two primer pairs resulted in compa- 
rable yields of the diagnostic bands  in the combinations 
B6/aB6+murine BMP-6 eDNA and B6/pA+transgene con- 
struct and no product in the  heterologous combinations 
(data not shown). While endogenous murine BMP-6 RNA 
is detected in skin, tongue, and stomach of normal mice 
and mice of lines VI-6-1  and VI-6-32, transgene-derived 
human BMP-6 RNA is detectable in the skin of transgenic 
mice of both lines and in oral mucosa of line VI-6-32, but 
not  in  stomach  (Fig.  4).  The yield of amplified product 
from skin using the B6/pA primer pair always exceeded 
Kpn 1 
I 
keratin 10 promoter 
1 kb 
Bam H][  (Sma l/Sal I)  (Sma l/Sal 1)  Kpn I 
beta-globin  hGH-pA 
BMP-6 eDNA  s gna 
Transcription  P, 
B 
Figure 1.  BMP-6 expression 
vector.  A  human  cDNA for 
BMP-6  was  brought  under 
the control of the bovine ker- 
atin  10  promoter.  A  beta- 
globin intron and a polyade- 
nylation  sequence  derived 
from  the  human  gene  for 
growth  hormone  were  in- 
cluded.  The black  rectangle 
represents  the region  of the 
construct which was used as a 
probe for in  situ  hybridiza- 
tion analysis. 
Blessing et al. BMP-60verexpression in Epidermis  229 Figure 2.  Phenotypes of BMP-6 transgenic mice. (a) Severely affected transgenic neonate (left) and control littermate (right). Note the 
absence of dermatoglyphic patterning and the tightly stretched skin of the transgenic founder.  (b) Moderately affected 7-d-old mice of 
line VI-6-1 (left, right)  and control littermate (middle).  The skin is shiny and flaky and eruption of hair shafts is delayed. (c) 8-wk-old 
mouse of line VI-6-1 (left) and normal control mouse (right).  (d) 5-mo-old mouse of line VI-6-1 with fully developed lesions and thick- 
ened ear lobes. (e) Paws of normal (left) and transgenic mice (right) of line VI-6-32. Note the swelling of the palms of the paws and toes 
as well as the abnormal nails of transgenic mice (e, inset). 
the yield obtained with the B6/aB6 primer pair, indicating 
an overexpression of exogenous BMP-6 over endogenous 
BMP-6 in transgenic skin. In addition, the ratio of endoge- 
nous BMP-6 signal to 13-actin signal in skin is comparable 
between transgenic lines and normal mice, indicating that 
there is no induction or repression of endogenous BMP-6 
on the RNA level by transgene derived-factor (Fig. 4). 
Expression of B MP-6 was also analyzed on the protein 
level  in  normal  and  transgenic  animals  (Fig.  5).  While 
there is strong and generalized expression of BMP-6 in in- 
terfollicular epidermis of normal neonates on the protein 
level (Fig. 5 a), there is only a very faint immunostaining in 
normal adult epidermis after prolonged incubation in the 
substrate solution (Fig. 5 b; sections in a, c,  and d  devel- 
oped for 30 rain in the substrate solution, the section in b 
for 4 h). In adult animals of the moderately affected trans- 
genic lines  VI-6-1  and VI-6-32,  however, BMP-6  protein 
was synthesized in a mosaic pattern both in interfollicular 
epidermis and in the infundibula of hair follicles (Fig. 5, c 
and d). There is  a  direct correlation between BMP-6  ex- 
pression  and  acanthosis.  While  regions  around  strongly 
staining cells  are  markedly  thickened,  adjacent  regions 
with weaker or no staining show no pronounced thicken- 
ing (Fig. 5 c). Because of the resemblance of protein distri- 
bution and relative amount of transgene-derived RNA as 
well as the absence of endogenous BMP-6 mRNA induc- 
tion, the majority of BMP-6  in  adult  epidermis  obtained 
from mice  of lines  VI-6-1  and  VI-6-32  is  most likely de- 
The Journal of Cell Biology, Volume 135,  1996  230 Figure 3.  Expression of transgene-derived RNA. Brightfield (a--c) and corresponding darkfield (a'--c') photomicrographs of in situ hy- 
bridization experiments on skin sections (a-b') from severely affected neonatal transgenic founders and (c and c') from a neonate of the 
moderately affected line VI-6-1. Note the strong and uniform labeling in the epidermis of the severely affected founder and the weak 
and patchy labeling in the neonate from a moderately affected line using a transgene-specific probe derived from the region preceding 
the polyadenylation signal in the human gene for growth hormone. Arrows point to labeling in interfollicular epidermis. Bars: (a) 200 
izm; (b and c) 50 Ixm. 
rived from the human transgene (Fig. 3, c and c', Fig. 4 and 
Fig.  5,  c  and  d).  Skin  sections  from  unaffected  adults  of 
lines VI-6-19 and VI-6-21 showed no difference in staining 
for BMP-6  when  compared  to  adult  skin  from  nontrans- 
genic controls,  suggesting  an inactive  transgene  (data  not 
shown). 
Histology of Transgenic Skin 
There  were  no  apparent  differences  in  epidermal  thick- 
Figure 4.  Agarose gel electrophoresis of RT-PCR assays using 
RNA from skin (lanes 1-3), oral mucosa (lanes 4-6), and stom- 
ach  (lanes  7-9)  of normal adult mice (lanes 1, 4,  and  7),  adult 
mice of lines VI-6-1 (lanes 2, 5, and 8), and VI-6-32 (lanes 3, 6, 
and 9). The primer pairs used were (a) B6/pA, which detect the 
transgene  derived transcript,  (b) B6/B6a,  which  detect endoge- 
nous  BMP-6 transcripts,  and  (c) actl/act2, which detect  13-actin 
transcripts. The sizes of the diagnostic bands are indicated on the 
right side in bp. 
ness  and  organization  between  the  class  of  severely  af- 
fected  neonatal  transgenic  founders  and  control  litter- 
mates (data not shown). However, skin from adult mice of 
lines VI-6-1 and VI-6-32 showed distinct features absent in 
normal skin (Fig. 6). The epidermis of 3-wk-old transgen- 
ics exhibited  marked  acanthosis  and  pronounced  parahy- 
perkeratosis  with diffuse manifestation  in line VI-6-1 and 
a less severe and more focal pattern in line VI-6-32. In the 
dermis  of these  transgenics,  we  observed  an  ongoing  in- 
flammatory process with  considerable  cellular  infiltration 
in  line  VI-6-1  and  weaker  inflammation  in  line  VI-6-32 
(Fig. 6, a  and b). Neutrophil-laden  pustules in the stratum 
corneum comparable  to Munro  microabscesses  of human 
psoriatic  lesions  were  present  (Fig.  6  c).  Ultrastructural 
analysis revealed a  higher  degree  of capillarization  in the 
dermis of transgenics  and  a  reduction  in number and size 
of hair follicles (Fig. 7, a  and b). While there are plenty of 
large guard hair follicles ranging down to the dermal-sub- 
dermal border in normal mice, this follicle type is missing 
completely in mice of line VI-6-1 and  is reduced  in num- 
bers  in mice of line VI-6-32.  The  dermal papilla  cells  are 
atrophic and there is strong hyperplasia in the upper part 
of the  outer root sheath.  Acanthosis  in transgenics  is due 
to multiple  layers  of nucleated  cells,  and  there  are  struc- 
tural  differences in the  stratum  corneum between normal 
and  transgenic  mice  (Fig.  7,  a  and  b).  The  regular  shape 
and smooth surface of a normal skin flake is in sharp con- 
trast to the highly irregular shapes of transgenic skin flakes 
Blessing et al. BMP-60verexpression  in Epidermis  231 Figure 5.  Expression of BMP-6 in the epidermis. Immunolocalization of BMP-6 in the epidermis of (a) a normal neonate, (b) a normal 
adult, (c) a transgenic adult of line VI-6-1, and (d) a transgenic adult of line VI-6-32. Note the strong and uniform interfollicular expres- 
sion in normal neonates (a) and the very weak staining in normal adults (b). Patchy expression is seen in adults from both transgenic 
lines (c and d). The arrows denote expression in interfollicular epidermis, arrowheads denote expression in infundibula of hair follicles. 
Bar, 50 ~m. 
(Fig. 7, c and d). In addition, transgenic skin flakes display 
a multitude of breaks and ridges on the surface resulting in 
fragility. 
Expression  of Integrin Subunits and Marker Keratins 
Expression of the et6-integrin subunit was analyzed in the 
skin of normal  adults  and moderately affected adults  of 
line VI-6-32 (Fig. 8). Immunostaining for this integrin sub- 
unit in normal adult epidermis was largely confined to the 
basal layer with the strongest reactivity towards the basal 
lamina and weaker staining in the lateral domains (Fig. 8, 
a  and  a').  In  acanthotic  epidermis  from moderately af- 
fected transgenic adults, there was generally stronger stain- 
ing for ct6-integrin in the basal layer of the epidermis and 
additional staining in suprabasal cells of interfollicular epi- 
dermis. The intensity of the staining both in basal and su- 
prabasal  cells  correlated  with  the  degree  of  epidermal 
thickening (Fig. 8, b and b'). 
Expression of the basal type keratin 14, the suprabasal 
differentiation markers keratins  1 and  10 and the hyper- 
proliferative marker keratin 6  were analyzed in severely 
affected  neonatal  founders  and  in  moderately  affected 
adults of lines VI-6-1 and VI-6-32. There were no apparent 
aberrations in the patterns of expression of keratins 1, 10, 
and  14 in severely affected neonatal transgenic founders 
when compared to normal neonates. Keratin 14 was pre- 
dominantly expressed in the basal layer and keratins 1 and 
10 were expressed in suprabasal layers (data not shown). 
Moderately affected adults  of lines  VI-6-1  and  VI-6-32, 
however, displayed aberrant expression of keratins  1, 10, 
and 14 (Fig. 9). Unusually thickened epidermis showed ex- 
pansion  of the  keratin  14  expression  domain  from  the 
basal  compartment  into  suprabasal  layers  including  the 
stratum corneum. In parallel, there was focal repression of 
the differentiation specific keratins 1 and 10 (Fig. 9, a- b"). 
Expression of the stress keratin 6 was similar in the epider- 
mis  of severely affected transgenic founders and normal 
neonates.  Keratin 6  expression was  largely restricted to 
the hair follicles and only very rarely small patches of su- 
prabasal interfollicular cells expressed this keratin (Fig. 9, 
c and d). In contrast to these findings and also to the ex- 
pression pattern in normal adult epidermis, moderately af- 
fected adults of lines VI-6-1 and VI-6-32 showed a strong 
interfollicular induction of keratin 6 in acanthotic epider- 
mis (Fig. 9, e and f). 
Proliferation  in Normal and Transgenic Skin 
Proliferation in normal and transgenic skin was evaluated 
by two different techniques. BrdU incorporation analysis 
was used to compare the distribution of S phase nuclei in 
the epidermis of normal adults and adults of lines VI-6-1 
and VI-6-32 (Fig. 10). Labeled nuclei were confined to the 
basal compartment in normal adult dorsal epidermis. By 
contrast, S phase nuclei were not only seen in abundance 
in the basal epidermal layer of moderately affected trans- 
genic adults but also were plentiful in the suprabasal epi- 
dermal compartments (Fig. 10, a and b). 
Proliferation in the skin of severely affected transgenic 
neonates was asessed by immunostaining for PCNA (Gar- 
cia et al., 1989). Epidermis from various body sites was an- 
alyzed and while there was always specific nuclear staining 
in basal interfollicular cells in normal epidermis, there was 
hardly any staining in the epidermis of severely affected 
transgenic neonates, and the few stained cells often showed 
aberrant cytoplasmic staining or were localized to supra- 
basal layers (Fig. 10, c-f). In summary, there is parahyper- 
keratosis with strong hyperproliferation in suprabasal epi- 
dermis of moderately affected adults  of lines VI-6-1  and 
VI-6-32, and strong repression of epidermal cell prolifera- 
tion in severely affected transgenic neonates. 
Discussion 
BMP-6 and Epidermal  Cell Proliferation 
The effect of BMP-6 on keratinocyte proliferation has been 
The Journal  of Cell Biology,  Volume 135, 1996  232 Figure 6.  Histology of transgenic  skin. Hematoxylin/eosin and chloroacetate esterase-stained  dorsal skin sections (a) from a 3-wk-old 
normal and (b) from a 3-wk-old transgenic mouse of line VI-6-1. There is acanthosis and hyperkeratosis in the transgenic skin as well as 
dermal infiltration.  The inset in b demonstrates parakeratosis in the epidermis from a 3-wk-old transgenic mouse of line VI-6-32. Note 
the remnants of nuclei present in the stratum corneum (arrowheads).  (c) Skin section from an adult of line VI-6-32 showing a pustule com- 
parable to Munro microabscesses. Bars: (a-c) 200 Ixm;  (Inset) 40 p,m. 
shown  to  be  strongly  inhibitory  in  cultures  transfected 
with a retroviral BMP-6 expression vector (Drozdoff et al., 
1994).  However, our study suggests a much broader spec- 
trum of possible BMP-6 effects on keratinocyte prolifera- 
tion in vivo: On one hand, strong and uniform overexpres- 
sion of the BMP-6 transgene in suprabasal cells leads to a 
repression of basal cell proliferation.  On the other hand, 
weak and mosaic expression of the BMP-6 transgene in in- 
terfollicular epidermis does not markedly affect neonatal 
skin  but  leads  to parahyperkeratosis and  hyperprolifera- 
tion  in  suprabasal  cells  after  day  6  postpartum.  These 
dose-dependent  alternative responses of keratinocytes to 
BMP-6  could be a  means of controling cell proliferation 
and  epidermal  thickness  in  late  gestation  and  newborn 
mice. By alternatively stimulating or repressing epidermal 
cell  proliferation  in  a  dose-dependent  manner,  BMP-6 
could change epidermal thickness and the number of su- 
prabasal cells, the source of BMP-6. Although this model 
is speculative and oversimplifies the mechanisms by which 
cell  proliferation  and  thickness  in  the  epidermis  is  con- 
trolled,  such  an  autoregulatory circuit  would  keep these 
parameters within certain boundaries.  There are striking 
similarities to the results obtained with two different trans- 
genic lines expressing an activated form of TGF-~3 in the 
epidermis, which either strongly repressed neonatal kera- 
tinocyte proliferation (Sellheyer et al., 1993)  or stimulated 
epidermal cell proliferation  in  undisturbed  adult  epider- 
mis (Cui et al.,  1995).  Our results with the BMP-6 trans- 
genics indicate that these differences could be due to the 
pattern  and strength of the TGF-[3 transgene expression. 
Although  the  presence of the  completely processed ma- 
ture factor was demonstrated in none of these studies, in- 
cluding ours, we are certain that transgene derived active 
BMP-6  protein  is  synthesized  because:  (a)  Both  human 
and murine cDNAs for BMP-6 have been shown t.o give 
rise to bioactive protein in various transfected cells includ- 
ing keratinocytes (Wall et al., 1993; Drozdoff et al., 1994; 
Gitelman et al., 1995); (b) We demonstrate the presence of 
transcripts derived from the human BMP-6 cDNA region 
encoding the mature region in RT-PCR experiments; and 
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genic skin. Survey transmission elec- 
tron  photomicrograph  of  skin  sam- 
ples  (a)  from  normal  and  (b)  from 
transgenic mice of line VI-6-1. Note 
the  reduced  thickness of the  dermis 
and  the  high  degree  of vasculariza- 
tion (black arrows) in the transgenic 
(b).  White  arrowheads  point  to  (a) 
normal and (b)  atrophic dermal pa- 
pilla cells in the transgenics. In addi- 
tion, the calibers of hair shafts (black 
arrowheads) are reduced, and there is 
hyperplasia in outer root sheath cells 
in these transgenics (white arrows in 
b).  (c  and d)  Scanning electron  mi- 
croscopy  of  skin  from  (c)  normal 
adults and (d)  adults of line VI-6-1. 
Note  the  regular  shape  and  smooth 
surface  of normal skin flakes  (c)  as 
opposed  to  the  highly  irregular 
shapes  and  brittle  surface  of  the 
transgenic flakes (d). Bars: (a  and b) 
420 Ixm;  (c and d) 0.7 I~m. 
The Journal  of Cell Biology,  Volume 135, 1996  234 Figure 8.  Distribution  of the e~6-integrin  subunit in skin. Differential interference contrast photomicrograph  of dorsal skin sections from 
(a) normal adults and (b) transgenic adults of line VI-6-32. (a' and b') Corresponding epifluorescence photomicrographs  after staining 
with et6-integrin-specific antibody GoH3. Note the confinement of a6-integrin to basal cells in normal skin (a') and the stronger basal 
and additional suprabasal staining in the epidermis of transgenic mice (b'). Bar, 50 jxm. 
(c) we demonstrate increased BMP-6 protein synthesis in 
adult transgenic versus normal epidermis without a visible 
induction of the endogenous gene as seen in the RT-PCR 
experiments. Unlike TGF-13, BMP-6 overexpression acti- 
vates suprabasal cell proliferation, whereas overexpression 
of TGF-[3 stimulated basal  cells (Cui et al.,  1995).  Also, 
BMP-6 derived from a native cDNA shows strong activity, 
implying that a substantial part of BMP-6 is properly pro- 
cessed and activated by keratinocytes in vivo. 
Because neonatal cultured keratinocytes that resemble 
a basal cell rather than a suprabasal cell can be directly in- 
hibited by BMP-6 (Drozdoff et at., 1994), we assume that 
in neonatal epidermis of severely affected founders, supra- 
basally  synthesized  BMP-6  directly  represses  basal  cell 
proliferation in  a  paracrine  fashion.  In  adult  epidermis, 
transgene-derived BMP-6 may induce suprabasal cell pro- 
liferation either directly in  an autocrine manner or indi- 
rectly in a paracrine manner by predisposing basal cells to 
continued proliferation after detachment from the  basal 
lamina. However, since nothing is known about BMP-6 re- 
ceptor distribution, this model remains speculative. 
BMP-6 and Epidermal Differentiation 
In vitro studies revealed that BMP-6 is switched on in cul- 
tured  keratinocytes  undergoing  terminal  differentiation 
before the appearance of the differentiation-specific ker- 
atins 1 and 10, making it an interesting candidate for trig- 
gering earliest events in this process (Drozdoff et al., 1994). 
A  direct  influence  on  the  expression  of  differentiation 
markers,  however,  was  not  established  in  keratinocytes 
transfected with a BMP-6 expression vector (Drozdoff et 
al., 1994). Similarly, we do not see major changes of marker 
keratin expression in our severely affected transgenic neo- 
nates, which, like the transfected keratinocytes, display re- 
duced  epidermal  cell proliferation. There  is  not  even a 
generalized interfollicular induction of the stress keratin 6 
as seen in comparable TGF-[3 transgenic mice with a simi- 
lar repression of keratinocyte proliferation and skin devel- 
opment (Sellheyer et al.,  1993). Therefore, strong overex- 
pression of BMP-6 in neonatal epidermis does not markedly 
change the usual distribution of differentiation markers. 
In parahyperkeratotic epidermis of moderately affected 
BMP-6 transgenics, we see major changes in keratin ex- 
pression.  BMP-6 inhibits  the  normal  pathway of kerati- 
nocyte differentiation in adult  epidermis and triggers an 
alternative  pathway  characterized  by  the  persistence  of 
keratin 14 in suprabasal layers, including the stratum cor- 
neum and the partial replacement of keratins 1 and 10 by 
keratin 6 and probably keratin 16. 
BMP-6 and the Psoriatic Phenotype 
It is well established that there are altered expression pat- 
terns for a variety of growth factors and their receptors in 
psoriatic skin as compared to normal skin including TGF-u, 
many cytokines, and TGF-[3 (Gottlieb et al., 1988; Elder 
et al., 1989; Kane et al., 1990; Krueger et al., 1990; Kupper, 
1990; Nickoloff et al.,  1991; Nanney et al.,  1992). Overex- 
pression of some of these factors, including TGF-13, in the 
epidermis of transgenic mice, however, did not evoke le- 
sions that could be viewed as murine equivalents of human 
psoriatic lesions either for lack of hyperproliferation and 
parakeratosis or the absence of dermal infiltrates (Vassar 
and Fuchs, 1991; Cheng et al.,  1992; Turksen et al., 1992; 
Blessing et al., 1993; Dominey et al., 1993; Guo et al., 1993; 
Sellheyer et al.,  1993; Cui et al.,  1995). With the exception 
of the thickening of the rete ridges that are absent in mu- 
rine dorsal epidermis, the moderately affected transgenic 
mice  overexpressing BMP-6  develop  skin  abnormalities 
with all characteristics of psoriasis in humans: parahyper- 
keratosis, changes in integrin and keratin expression, the 
abnormally formed nails, the brittle and fragile skin flakes, 
extensive dermal capillarization, the presence of dermal 
infiltrates, and lesions resembling Munro microabscesses 
(Lever and  Schaumburg-Lever, 1975;  Weiss  et  al.,  1984; 
Blessing et al. BMP-60verexpression  in Epidermis  235 Figure 9.  Distribution of keratin components in normal and transgenic skin. (a and b) Expression of keratins 1, 10, and 14 as shown by 
double  label immunofluorescence staining.  Differential  interference  contrast  of 5-1~m skin  sections from  (a)  normal  adults  and  (b) 
adults of line VI-6-32. Expression of keratin 14 is demonstrated by labeling with monoclonal antibody CKB1 (a' and b'), expression of 
keratins 1/10 is shown by labeling with monoclonal antibody 8.6 (a" and b"). Note the expansion of keratin 14 expression into supra- 
basal layers in thickened epidermis of transgenic adults (b') and the focal repression of keratins 1 and  10 (arrowhead in b"). Arrows 
mark the basal layer of the epidermis. (c-f) Expression of keratin 6 as demonstrated by immunostaining using a polyclonal antibody on 
skin sections from (c) normal neonates, (d) severely affected neonatal founders, (e) normal adults, and (f) transgenic adults of line VI-6-1. 
Note the staining in the outer root sheaths of all specimen (arrowheads) and the absence of staining in interfollicutar epidermis of nor- 
mal mice (arrows in c and e). Weak and patchy staining is seen in epidermis from the severly affected founder (arrows  in d), and strong 
interfollicular expression is seen in transgenic epidermis from adults of line VI-6-1 (arrows in f). Bars: (a, b, e, and f) 50 tzm; (c and d) 
100 ~m. 
The Journal of Cell Biology, Volume 135, 1996  236 Figure 10.  Proliferation in normal and transgenic epidermis. Anti-BrdU staining on sections of labeled skin from (a) normal adults and 
(b) a transgenic  adult of line VI-6-32. In normal and transgenic  skin, many labeled nuclei are found in the basal layer of interfollicular 
epidermis (arrows  in a and b). In the transgenic adult, additional  strong staining of many nuclei is seen in suprabasal layers (arrowheads 
in b). Anti-PCNA staining  (PC10 antibody)  of skin sections from (c and d) normal neonates  and (e and f) severely affected transgenic 
founders from (c and e) the mid-dorsum and (d and f) facial regions (cheek). Note the abundant nuclear staining in basal interfollicular 
keratinocytes in normal skin from different body sites (arrows  in c and d) and the rare and aberrant cytoplasmic staining in basal cells of 
transgenic epidermis (arrows  in e and f) and suprabasal  cells (f). Bars, 100 Ixm. 
Stoler et al., 1988; Wade and Finan, 1990; Watt and Hertle, 
1994). An important question is if the disturbances seen in 
the  epidermis  are  a  primary result of epidermal overex- 
pression of BMP-6 or if BMP-6 expressed in skin or other 
epithelia first become systemic and then trigger responses 
that  result  in  skin  aberrations.  There  are  several  facts 
which speak against the indirect model and favor a model 
where  the  epidermal aberrations  are  a  primary result  of 
BMP-6 overexpression in the epidermis: (a) There is no in- 
duction of ectopic cartilage or bone formation which would 
be expected if BMP-6 diffused into the dermis (Wozney et 
al., 1988; Gitelman et al., 1994);  (b) Unlike TGF-[3, BMP-6 
does not seem to achieve systemic levels or to exert long 
range  effects.  Even  if transfected  CHO  cells  producing 
BMP-6 are allowed to form massive solid tumors in mice, 
there are only local effects on cartilage induction,  and no 
generalized systemic or epidermal changes have been re- 
ported (Gitelman et al., 1994);  (c) Full thickness grafting 
experiments show that epidermal aberrations of the trans- 
genic graft are  maintained  on  a  nontransgenic  host;  and 
(d)  Acanthosis  and  hyperkeratosis coincide  with  the  ex- 
pression of BMP-6.  In conclusion, this is strong evidence 
that  the  skin  phenotype  in  our  BMP-6-overexpressing 
mice is a direct result of epidermal BMP-6 expression and 
is not evoked by growth retardation or systemic levels of 
BMP-6.  Dermal changes such as inflammation or dermal 
papilla atrophy are most likely secondary effects due to cy- 
tokines  or  growth  factors  produced  by activated  kerati- 
nocytes (Gottlieb et al., 1988; Elder et al., 1989; Kane et al., 
1990;  Krueger et al., 1990; Kupper, 1990;  Nickoloff et al., 
1991;  Nanney et  al.,  1992).  These  findings  together  with 
our  observation  that  epidermal  aberrations  precede  in- 
flammation  in  the  transgenics  suggest  that  psoriasiform 
dermatitis  is  primarily a  disease  of the  keratinocyte and 
not of the immune system as has been debated (see Gott- 
lieb et al., 1995 vs Carroll et al., 1995). 
Changes  in  expression  of  quite  unrelated  molecules, 
however, are also able to evoke psoriasis-like lesions in an- 
imal  models  (Hammer et  al.,  1990;  Carroll  et  al.,  1995; 
Bullard et al., 1996).  Transgenic mice with an altered inte- 
grin expression pattern in the epidermis and mice carrying 
a  hypomorphic  CD18  mutation  are  among  those  that 
closely reflect the human condition, again with the excep- 
tion of the thickening of rete ridges (Carroll et al.,  1995; 
Bullard et al., 1996).  Therefore, distinct etiological agents 
belonging to  as  different categories as  growth factors or 
cell adhesion molecules could be responsible for different 
types  of psoriatic  lesions  in  humans.  This  hypothesis  is 
supported by the fact that there are distinct differences be- 
tween the integrin-induced and the BMP-6-induced psori- 
asis models. The integrin transgenic mice show spontane- 
ous episodes of remission resembling the human condition 
psoriasis  vulgaris.  By  contrast,  the  BMP-6  transgenics 
never went into complete remission and suffered from ex- 
tremely strong inflammatory processes resembling severe 
human  erythrodermic  types  of  psoriasis.  On  the  other 
hand,  growth  factors of the  TGF-[3 superfamily regulate 
integrin expression in keratinocytes (e.g., Zambruno et al., 
1995).  Similarly, BMP-6 overexpression in our transgenic 
mice evoked  a  change  in  %  integrin  subunit  expression 
which was also seen in the  [31 integrin subunit  transgenic 
mice  developing  psoriatic  lesions  (Carroll  et  al.,  1995). 
Thus, changes in growth factor activities appear to be up- 
stream of the changes in expression of integrin cell adhe- 
sion  molecules  or  cytoskeletal  components  like  keratins 
during the process of psoriatic plaque formation. We are 
currently  in  the  process  of characterizing  the  epidermal 
expression  pattern  of BMP-6  in  patients  with  psoriasis. 
Preliminary results suggest a strong but patchy expression 
in  the  epidermis  of  some  of  these  patients.  Therefore, 
BMP-6 is a prime candidate for a growth factor sponsoring 
the formation of psoriatic lesions in humans. 
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